Because of their postmitotic nature, neurons are difficult subjects for gene transfer. To circumvent this, we have used a defective herpes simplex virus vector to overexpress the rat brain glucose transporter (GT) gene under the control of the human cytomegalovirus iel promoter. This vector, designated vIElGT, was propagated using a herpes simplex virus type 1 temperature-sensitive mutant, ts756. GT expressed from vIElGT was readily immunoprecipitated from membrane fractions of vIElGT-infected Vero cells. By using indirect double immunofluorescence techniques, vIElGT was shown to be capable of enhancing GT expression in cultured hippocampal neurons and glia. Glucose transport in such vIElGT-infected cultures was increased -2-fold relative to controls. The efficacy of this system in vivo was then tested by microinjection of vIElGT into adult rat hippocampus. When examined 2 days later, GT expression from vIElGT was demonstrated in hippocampal neurons by in situ hybridization; a small but significant increase in glucose transport was detected in tissue immediately surrounding the injection site by 2-deoxy[14C]glucose uptake and autoradiography. Such iinjections did not cause marked cytopathology. Thus, this approach can be used to alter central nervous system physiology in vitro and in vivo.
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Because of the postmitotic nature of neurons, gene transfer to these somatic nondividing cells requires innovative approaches; use of herpes simplex virus (HSV) vectors may represent such an approach. HSV-1 and HSV-2 are wellknown neurotropic agents capable of replication and latency in the peripheral nervous system. In addition, work in experimental animals and in the natural human host has shown that these viruses also interact with neurons in the central nervous system (CNS). Recombinant HSVs have been employed as vectors of foreign genes in cultured cells (1) (2) (3) (4) (5) and have been used to express an indicator gene (Escherichia coli lacZ gene) in sensory neurons or in CNS during acute growth and latency (6) (7) (8) (9) (10) (11) .
Recent development of HSV vectors has capitalized on the natural occurrence of defective interfering particles that arise during high-multiplicity propagation of HSV (12) . These defective viruses contain DNA molecules that are the same size as standard virus (152 kbp) but consist of head-to-tail concatemers of small regions of the viral genome including an origin of DNA replication (oris or oriL) and a cleavage/ packaging signal (a sequence). Defective viruses replicate and package only in the presence of a replication-competent helper virus. This phenomenon was extended to the construction of cloning-amplifying vectors (termed amplicons) consisting of a prokaryotic plasmid for amplification in bacterial host along with the important cis-acting HSV regulatory sequences for propagation in eukaryotic cells (13) . Any eukaryotic transcription unit may be included on amplicons and propagated with helper virus to transfer genes into eukaryotic cells. Such defective HSV vectors have been used to express foreign genes in cultured cells, including neurons (14, 15) . Although Kaplitt et al. (16) have used a defective HSV vector to express an indicator gene in adult rat brain, to our knowledge, no one has reported the use of HSV vectors, albeit intact or defective, to alter the physiology of the CNS in adult animals. In this study, we have employed a defective HSV vector to deliver the brain-type glucose transporter (GT) into primary hippocampal neurons in vitro and into the hippocampus. This particular gene was chosen as the first step in a strategy to deliver more glucose to hippocampal neurons, to buffer them from the neurotoxic effects of a number of metabolically disruptive neurological insults (see Discussion). We find that in vitro and in vivo, expression of the newly introduced GT gene is associated with increased glucose uptake.
MATERIALS AND METHODS
Cells and Virus. Mixed neuronal/glial cultures and enriched glial cultures were prepared from the hippocampi of fetal Sprague-Dawley rats on the 18th day of gestation as described (17) . Mixed neuronal/glial cultures were maintained in MEM-PAK (a modified minimal essential medium purchased from the cell culture facility of University of California, San Francisco) supplemented with 10% (vol/vol) horse serum (HyClone) and were used at -10 days of age when the neuron/astrocyte ratio was z50:50, as determined by immunocytochemical staining (data not shown). The glial cultures were maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO/BRL) supplemented with 5% (vol/vol) fetal calf serum (HyClone). Vero cells (ATCC CCL81) were maintained in DMEM/10%o (vol/vol) NuSerum (Collaborative Research). All cells are maintained in a 5% C02/95% air atmosphere. ts756 (HSV-1 KOS) has a temperature-sensitive mutation in an essential regulatory gene encoding ICP4 and was provided by R. G. Hughes, Jr. (Rosewell-Park Cancer Institute, Buffalo, NY).
Construction of Amplicons. The amplicon pIElGTori was constructed as follows: The GT coding sequence was isolated from prGT3 (kindly provided by Morris J. Bimbaum, Harvard University) as an EcoRI-Bgl II fragment and cloned into pG310, an expression vector provided by Lidia Sambucetti (Stanford University). pG310 contains the promoter, exon 1 (untranslated), and intron 1 (from nt -1021 to +947), and the poly(A) signal (from nt +3270 to +3430) of the human cytomegalovirus (HCMV) iel gene in a pGEM-2 background. This plasmid was derived from pON308G (18) by first deleting the pGEM-2 sequences between EcoRI and BamHI, deleting the iel coding sequences (exons 2-4) between the Abbreviations: HSV, herpes simplex virus; GT, glucose transporter; 3-Gal, ,B-galactosidase; X-Gal, 5-bromo-4-chloro-3-indolyl P-Dgalactopyranoside; pfu, plaque-forming unit; CNS, central nervous system; HCMV, human cytomegalovirus; MAP2, microtubuleassociated protein 2; GFAP, glial fibrillary acidic protein.
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Pst I site (nt +947) and the BamHI site (nt +3270), and inserting a linker with a unique EcoRI site downstream of the splice acceptor of intron 1. The GT gene was cloned into the EcoRI site and transcription of GT is terminated by the iel poly(A) signal. The HSV-1 oris (295 bp, from strain F) and the a sequence (330 bp, from strain KOS) were then isolated from pON812 as an Xba I fragment and inserted downstream ofthe poly(A) signal. pON812 was constructed by Jeffrey Viera (Stanford University) by cloning the a sequence (19, 20) isolated from pUC18-19 (kindly provided by James Smiley, McMaster University) as a BamHI fragment and the oris was isolated from pON103 (21) as a HindIII-EcoRI fragment into a cloning vector pIC-20H (22) . The construction of pIEl1,galori is similar to that of pIElGTori, except that the GT gene and the HCMV iel poly(A) signal were replaced by an EcoRI-Xba I fragment from pON3 (23) Immunofluorescence. GT with microtubule-associated protein 2 (MAP2) or glial fibrillary acidic protein (GFAP) were colocalized on 10-day-old mixed neuronal/glial cultures grown on chamber slides. The cultures were mock-infected, infected with vIElGT, or infected with vIEl/3gal at -0.1 pfu per cell. Sixteen hours after infection, the cells were fixed with acetone/methanol, 3:1 (vol/vol), and GT expression was detected with anti-GT rabbit serum (1:400 dilution), followed by rhodamine-conjugated goat anti-rabbit IgG antibody (1:80 dilution; Tago). Neurons were identified using a mouse MAP2 monoclonal antibody (1:100 dilution; Sigma) and astrocytes were identified using a mouse GFAP monoclonal antibody (1:200 dilution; Sigma). MAP2 (15 ,um thick) were prepared for hybridization as described (25) . The 
RESULTS

Construction of Amplicons and Generation of Defective
Vectors. We constructed an amplicon carrying a cDNA encoding the Glut-1 isoform of GT, initially isolated from rat brain endothelium (27, 28) . The GT gene was put under the control of the HCMV iel promoter-enhancer, which allows constitutively strong expression in many different cell types. A test amplicon (pIElGTori) and a control amplicon (pIEl/3galori, containing the E. coli lacZ gene in place of GT)
were constructed (Fig. 1) . We used ts756 (29) , an HSV-1 temperature-sensitive mutant, as the helper virus. ts756 has a mutation in ICP4, an essential regulatory a gene ofthe virus and is completely replication-defective at 39°C. Defective virus vectors were generated by cotransfecting pIElGTori or pIE1.8galori along with genomic DNA of ts756 into Vero cells and then serially passaging the viral stocks at 33°C by using a 1:4 dilution to encourage growth of defective virus. The virus stocks thus generated from pIElGTori and pIE13galori are referred to as vIElGT and vIE1,8gal, respectively.
Immunoprecipitation of GT from vIElGT-Infected Vero Cells. We first confirmed that vIElGT enhanced GT expression in Vero cells. A new species of -41 kDa was immunoprecipitated from membrane fractions from vIEIGT-infected cells (Fig. 2, lane 3) but not in mock-infected or vIEl18gal-infected controls (Fig. 2, lanes 1 and 4, respectively) . In the presence of tunicamycin, this product was reduced to =38 kDa (Fig. 2, lane 2) , the reported size of the primary translation product of Glut-i (28) . The endogenous GT in rat brain endothelium is known to be heterogeneously glycosylated with a mean molecular mass of -52 kDa (27) , and alternative GT species of 45-47 kDa also occur in rat brain (27, 28) . Thus, the 41-kDa GT that we observed probably results from differential glycosylation in Vero cells.
Efficacy of Infection with vIElGT in Cultured Neurons and Astrocytes. We next tested the ability of vIElGT to express GT in primary cultures of hippocampal neurons and astrocytes by using immunofluorescence. GT immunoreactivity was observed in vIElGT-infected cultures (Fig. 3) colocalize neuron-specific antigen MAP2 or glia-specific antigen GFAP with GT immunoreactivity, both neurons and astrocytes were found to be capable of expressing GT (Fig.   3) . Similarly, p3-Gal-expressing neurons or astrocytes were observed in vIE13gal-infected but not in vIElGT-infected or mock-infected cultures (data not shown).
Given that our goal was to manipulate cellular function with these interventions, we tested whether increased GT (Fig. 4) . Mock infection or infection with vIElfgal did not alter transport.
Efficacy ofInfection with vIElGT and vIElfiJa in Vivo. We next tested the ability of vIElGT to express GT when injected into the hippocampus of adult rats by using in situ hybridization techniques. To distinguish the viral vector-.coO Proc. Natl. Acad. Sci. USA 90 (1993) derived GT mRNA from the endogenous version, a 75-nt oligonucleotide probe antisense to the iel promoter from nt -35 to +40 was used. This probe hybridized to the 5' untranslated end of both the GT transcripts from vIElGT and the lacZ transcripts from vIEl3gal. Hybridization signals were readily detected in hippocampus microinfused with vIElGT (Fig. 5A) or vIElpgal (Fig. 5B) ; in contrast, no such signal was detected after injection with the helper virus or with DMEM alone (data not shown). The signals were clustered around the injection site and highly concentrated along the dentate gyrus. The pattern of vIE1,Bgal expression as visualized by in situ hybridization was similar to that visualized by histochemical staining with X-Gal (Fig.  5C ).
We further characterized the parameters of expression with the HSV system by injecting vIEl1,gal and staining with X-Gal. (Gal expression was analyzed 2, 4, and 7 days after injections; expression peaked at day 2. At that time, expression was localized immediately surrounding the injection site, with most positive cells within a 150-,um radius. Within that area, :5% of cells expressed (-Gal. Of those cells, :'82% were found to be neuronal by morphological criteria. The number of cells that expressed 3-Gal within the 150-,um radius of the injection site was -50% of the peak value by 4 days after injection and declined to zero by 7 days. We then tested whether injection of vIElGT altered glucose uptake in the CNS of adult rats. vIElGT was microinfused unilaterally into the hippocampus and vIEl,Bgal was microinfused contralaterally; 2-deoxy[14C]glucose uptake was assessed 2 days later. Because of the data for the spatial distribution of 13-Gal-positive cells, we analyzed glucose uptake within a small sphere of tissue, with a radius of "'450 Am, surrounding the injection site (corresponding to the dorsal blade of the dentate gyrus).
Glucose transport was enhanced a significant 10o at the injection site on the vIElGT side, relative to the contralateral side. This enhancement declined with increasing distance from the infusion site, and uptake was equivalent to that on the contralateral side within "180 ,um of the injection site (Fig. 6 ). There were no differences in uptake in hippocampal regions more distant from the injection site (data not shown). Such an increase might be physiologically meaningful within the tightly regulated realm of cerebral metabolism (32) .
As noted, our studies utilized the HCMV iel promoterenhancer and a temperature-sensitive mutant of HSV as helper. Although the strength of the HCMV promoterenhancer is well established, its long-term pattern of expression in neurons is unclear. We observed (-Gal-expressing cells in rat hippocampus only for the first few days after infection, in agreement with a report (16) that also used the HCMV iel promoter to express lacZ. We (7) and others (10) have demonstrated that the latency-associated transcripts (LAT) promoter from HSV-1 can cause long-termed gene expression in latently infected animals. Thus, the LAT promoter and other promoters from housekeeping genes may be more effective at causing sustained changes in CNS function. With respect to the helper virus, the internal body temperature of the rat is not completely nonpermissive for ts756 replication and we have observed some cytopathicity in the hippocampus by using ts756 (unpublished data). Viruses carrying deletion mutations in key regulatory genes such as ICP4 and ICPO will potentially facilitate this technique (33) .
These studies were initiated to find a somatic gene therapy to alter neuronal function and potentially protect neurons from insult. The choices of attempting to enhance glucose transport and using the hippocampus were not random. The brain is exquisitely dependent upon glucose; nervous tissue has extremely high metabolic rates, utilizes little other than glucose, and stores it poorly (34) . Moreover, neurological insults such as hypoxia-ischemia, hypoglycemia, and sustained seizure disrupt energy charge in the brain and preferentially damage the hippocampus; in the case of sustained seizure, glucose transport can become the rate-limiting step determining whether there is a damaging mismatch between energy delivery and utilization (32) . Furthermore, glucocorticoids damage hippocampal neurons and enhance the toxicity of these neurological diseases; this endangerment is energetic in nature, as it can be lessened by supplementation of the hippocampus with excessive glucose (35) . Finally, neuron death emerges slowly over the 48-72 h after these neurological insults and a number of pharmacological interventions during this delayed period can be neuroprotective (35) ; thus, were the rat hippocampus exposed to vIElGT immediately after onset of the insult, glucose transport would be enhanced during the time window of vulnerability. As noted, the enhancement of glucose transport in the small set of affected neurons was probably well in excess of 10%o above control values; there is reason to believe that with optimization of the protocol described here, the percentage of neurons so affected and/or the magnitude of the effect can be improved. Our data suggest that this method of intervention might have neuroprotective potential.
